AbbVie cites growth of immunology business in the second quarter

An earlier mentation of this study incorrectly cited AbbVie's updated EPS guidance for 2021. It has been corrected.

AbbVie Inc. ABBV, +0.27% bushed expectations for the 2nd 4th of 2021, driven mostly by gains successful its immunology business. The cause shaper had net of $766 million, oregon 42 cents per share, successful the 2nd 4th of 2021. It had a nonaccomplishment of $738 million, oregon 46 cents per share, successful the aforesaid 4th a twelvemonth ago. Adjusted net per stock were $3.11, against a FactSet statement of $3.08. AbbVie said its gross jumped to $13.9 cardinal for the quarter, up from $10.4 cardinal successful the aforesaid play a twelvemonth ago. The FactSet statement was $13.6 billion. The institution said income of respective marquee drugs accrued successful the 2nd quarter, including arthritis therapy Humira to $5.0 cardinal and Botox Cosmetic, which the cause shaper gained arsenic portion of its acquisition of Allergan, to $584 million. The institution updated its guidance for the year, saying it present expects EPS of $6.04 to $6.14, compared with past guidance of $7.27 to $7.47. It besides updated guidance for adjusted EPS and present expects a scope of $12.52 to $12.62, compared with erstwhile guidance of $12.37 to $12.57. AbbVie's banal is up 10.4% truthful acold this year, portion the broader S&P 500 SPX, +0.42% is up 17.6%.